Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
R3i editorial
18 September 2016

Prof. Jean Charles Fruchart, Prof. Michel Hermans, Prof. Pierre Amarenco
New study links elevated triglycerides with plaque progressionRead more...

Genetic studies show that elevated triglycerides (a marker for triglyceride-rich lipoproteins and their remnants) are causal for atherosclerotic cardiovascular disease. Yet definitive evidence for a relationship between achieved triglycerides and progression of atherosclerotic plaque, as previously demonstrated for low-density lipoprotein cholesterol (LDL-C) , has been lacking.
Consequently, this month’s Focus article , the first study to show that on-treatment triglyceride levels, especially above 200 mg/dl (2.3 mmol/L) associate with coronary plaque progression, even in patients with controlled LDL-C levels, is of paramount importance...
PCSK9 and Atherosclerosis
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professors Jean Davignon (Vice-President of the R3i foundation), Jean-Charles Fruchart (President of R3i) and Michel Hermans (R3i General Secretary), the latest downloadable deck of 242 slides discusses the potential role for anti-PCSK9 mAbs in the future management of cardiovascular disease.
landmark study
18 September 2016

TINSAL-CVD does not rule out a role for inflammation as a contributor to residual cardiovascular risk Read more...

While lipids have attracted most of the attention in interventional studies targeting residual cardiovascular risk, it is recognized that other variables may also contribute. In particular, the role of chronic subclinical systemic inflammation has attracted attention.  This factor may be of particular relevance in individuals...
focus on...
18 September 2016

New analysis supports targeting non-HDL cholesterol, triglycerides to reduce plaque progressionRead more...

The results of this pooled analysis reaffirms the importance of targeting non-HDL-C, which comprises all atherogenic apolipoprotein B-containing lipoproteins, to reduce coronary plaque progression. As shown by this study, the antiatherosclerotic benefit of lower non-HDL-C levels was evident even in patients with well controlled LDL-C...
recent publication

News from ESC Congress 2016 Rome
Updated ESC/EAS dyslipidaemia guidelines launchedRead more...

An update to the 2011 Joint Guidelines for management of...
recent publication

News from ESC Congress 2016 Rome
Triglyceride/HDL ratio predicts multivessel coronary artery disease in ACSRead more...

A triglyceride/high-density lipoprotein cholesterol (TG/HDL) ratio ?1.76 is an independent...
recent publication

Controversy about lipid fractions and risk for CAD and diabetesRead more...

A study using Mendelian randomization highlighted an association between elevated...
recent publication

SPIRE outcomes studies with bococizumabRead more...

Although statins significantly reduce vascular event rates, lipid-related residual cardiovascular...
recent publication

Is the polypill a cost-effective option to reduce residual cardiovascular risk?Read more...

In the Spanish healthcare setting, the polypill (aspirin 100 mg,...

What is residual risk ?

Residual risk of vascular events persisting in patients at treatment goals according to current standards of care or failing to meet goals, including risk related to dyslipidemia, high blood pressure, hyperglycemia, systemic inflammation and unhealthy lifestyles.

What is the Initiative ?

The R3i, a worldwide, academic, multidisciplinary non-profit organization, aims to successfully address the excessively high risk of macro- and micro-vascular complications in patients with atherogenic dyslipidemia, characterised by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol and unaddressed by current standards of care.